In vivo octreotide administration acutely reduces exocrine granule size in the human pancreas.
BACKGROUND
Octreotide has been found to be effective in the prevention of postoperative complications of pancreatic surgery, but the benefit of preoperative octreotide administration has not been assessed.


OBJECTIVE
To evaluate the ability of octreotide in reducing the amount of digestive enzymes in the pancreas before surgery, a morphometric ultrastructural study of the gland was undertaken in patients undergoing demolitive pancreatic surgery.


METHODS
Twenty-three inpatients received saline (n = 8) or octreotide (100 micrograms s.c.) before surgery either once (n = 5), or three (n = 5) or six (n = 5) times at 8-hour intervals. At surgery, biopsies of the pancreas were taken and processed for electron microscopy. Several parameters were assessed in exocrine cells by means of ultrastructural morphometry.


RESULTS
A single administration of octreotide significantly reduced the exocrine granule number and the mean and total granular surface sectional area, and the ratio between granule area and cytoplasmic area. Repeated octreotide administrations were associated with partial (3 administrations) and complete (6 administrations) recovery of all parameters to control values.


CONCLUSIONS
Preoperative administration of octreotide, the synthetic analogue of somatostatin, acutely reduces exocrine granule number and size in the pancreatic cell. This finding can partially explain the prophylactic effect of the drug on early complications of pancreatic surgery. Such an effect is not maintained over multiple administrations of the somatostatin analogue. Possible explanations for this latter finding are discussed.
Falconi
M
M
Departments of Surgical and Gastroenterological Sciences, Section of Anatomy and Histology, University of Verona, Strada Le Grazie, 8, I-37134 Verona, Italy.
Caldiron
E
E
Zancanaro
C
C
Benati
D
D
Talamini
G
G
Bassi
C
C
Pederzoli
P
P
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000494:pharmacology*; D010179:Pancreas / Q000033:anatomy & histology* / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000601:surgery; D012016:Reference Values; D022142:Secretory Vesicles / Q000187:drug effects / Q000648:ultrastructure*
D015282:Octreotide